"Your health and safety are always our top priority. To help you protect yourself and your loved ones, we’ve gathered the most important information and guidance on the coronavirus and COVID-19. Go to our website. You have many ways to get care without leaving the comfort of your home - including an e-visit, phone, video appointments, and email. This allows you to still get great care while helping to address the community spread of COVID-19. If you’re concerned about your specific health condition, call 1-833-KP4CARE (1-833-574-2273) (TTY 711) to talk to a licensed care provider 24/7. For answers to your general questions about COVID-19, call our new information line for Kaiser Permanente members at 1-877-813-7297."

During the past decade, Kaiser Permanente-San Marcos conducted 95 clinical trials. In the 10-year time frame, 95 clinical trials started and 55 clinical trials were completed, i.e. on average, 57.9% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 36 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kaiser Permanente-San Marcos" #1 sponsor was "National Cancer Institute (NCI)" with 64 trials, followed by "SWOG Cancer Research Network" with 30 trials sponsored, "Alliance for Clinical Trials in Oncology" with 7 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 6 trials sponsored and "Hoffmann-La Roche" with 6 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kaiser Permanente-San Marcos" #1 collaborator was "National Cancer Institute (NCI)" with 53 trials as a collaborator, "NRG Oncology" with 12 trials as a collaborator, "Canadian Cancer Trials Group" with 6 trials as a collaborator, "Astellas Pharma US, Inc." with 2 trials as a collaborator and "Astellas Pharma Inc" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Kaiser Permanente-San Marcos" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Lung Cancer AJCC v8" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Stage IVA Lung Cancer AJCC v8" (7 trials) and "Stage IVB Lung Cancer AJCC v8" (7 trials). Many other conditions were trialed in "Kaiser Permanente-San Marcos" in a lesser frequency.

Most popular intervention types in "Kaiser Permanente-San Marcos" are "Drug" (100 trials), "Other" (81 trials), "Biological" (59 trials), "Procedure" (33 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (45 trials), "Quality-of-Life Assessment" (28 trials), "Computed Tomography" (19 trials), "Biospecimen Collection" (18 trials) and "Nivolumab" (18 trials). Other intervention names were less common.

The vast majority of trials in "Kaiser Permanente-San Marcos" are 106 trials for "All" genders, 20 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Kaiser Permanente-San Marcos". undefined are not yet recruiting, 24 are recruiting, 65 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Kaiser Permanente-San Marcos, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Kaiser Permanente-San Marcos, 0 "Phase 1" clinical trials were conducted, 61 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".